Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation
Cardell, Chelsea F. , Segovia, Diana, Prakash, Laura R. , Zemla, Tyler , Shi, Qian , Ahmad, Syed, Snyder, Rebecca A. , O'Reilly, Eileen M , Katz, Matthew H G , Snyder, Rebecca A , Shi, Qian , Zemla, Tyler J , Segovia, Diana, Prakash, Laura R. , Herman, Joseph M. , O’Reilly, Eileen M. , Katz, Matthew H. G. , Snyder, Rebecca A.

JCO Oncology Practice | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-01431 | PMID 42485590 Get It

PURPOSE Adherence to operative standards and thorough documentation of surgical technique are critical, particularly in multidisciplinary clinical trials. We sought to evaluate variability in the performance and documentation of oncologically relevant aspects of technical surgery among patients enrolled in Alliance A021501, a phase 2 National Clinical Trials Network randomized clinical trial of neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma. METHODS We reviewed the primary operative and pathology reports of all enrolled patients who underwent complete pancreatic resection. Operative techniques and pathologic end points with potential to influence recurrence and survival were evaluated. RESULTS Fifty-one of 126 study participants (40.5%) underwent complete pancreatectomy. The extent of lymphadenectomy was documented in 36 (70.6%) operative reports, and 5 (9.8%) reports outlined the specific lymph node stations removed. Periadventitial dissection of the superior mesenteric artery was described in 25 of 50 (50.0%) operative reports. Immediate histopathologic analysis of the hepatic duct and pancreatic parenchyma margins was documented in 29 of 50 (58.0%) and 32 of 49 (65.3%) reports, respectively, and presence or absence of residual disease following resection was documented in 9 of 51 (17.6%) reports. Specimen orientation was documented in 19 of 51 (37.3%) pathology reports, and 30 of 49 (61.2%) pathology reports stated the distance between the tumor and final SMA margin. CONCLUSION Even in this rigorously controlled, multicenter, randomized pancreatic cancer clinical trial, performance of key elements of technical surgery was inconsistent, and documentation was incomplete. Standardization of technique and documentation in clinical trials and within clinical practice should be addressed to improve quality assurance and trial interpretability.
Acoustic and Perceptual Characteristics of Compressed Dysarthric Speech: Implications for Teleassessment
Tran, Kelvin , Utianski, Rene L. , Liss, Julie , Berisha, Visar , Liss, Julie M , Utianski, Rene L , Tran, Kelvin , Berisha, Visar

Journal of Speech, Language, and Hearing Research | July 22, 2026 | Volume: 69 | Issue: 8 | Pages: 3541-3552

10.1044/2026_jslhr-24-00726 | PMID 42485489 Get It

Purpose: This study aimed to evaluate how speech signal compression algorithms affect the acoustic and perceptual characteristics of dysarthric speech. As telepractice becomes more common in speech-language pathology, particularly in the assessment of dysarthria, understanding the impact of telecommunication compression on speech fidelity is essential for clinical decision making. Method: Speech samples were collected from 15 individuals with dysarthria, recorded locally and simultaneously via Zoom (Version 6.2.11). The Opus codec was used to process the locally recorded speech samples under fullband, wideband, and narrowband compression conditions. Acoustic measures were derived for all samples. Twenty experienced speech-language pathologists (SLPs) rated vocal quality and nasality for sustained vowels and rated articulatory precision and orthographically transcribed sentences across each condition. Results: Narrowband compression was associated with significantly degraded voice quality measures (e.g., harmonic-to-noise ratio, shimmer) and reduced transcription accuracy. Despite these changes in acoustics and intelligibility, ratings of articulatory precision, nasality, and vocal quality remained stable across conditions, suggesting SLPs could adjust for compression artifacts when making perceptual judgments. Conclusions: Speech compression, particularly in low-bandwidth (i.e., narrow) condition, impacts acoustic fidelity and intelligibility, though expert listeners maintain reliable perceptual judgments. These findings underscore the need to consider compression effects in telepractice and highlight the importance of developing optimized protocols for remote dysarthria assessment.
Photon-Counting CT in Pediatric Imaging: Point—Essential to the Future of CT for Children
Horst, Kelly K.

American Journal of Roentgenology | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2214/ajr.26.35581 | PMID 42485401 Get It

Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study
Eldesouki, Mohamed H. , Hafez, Youssef , Salem, Ahmed , Alomari, Mohammad , Hashash, Jana, Farraye, Francis A. , Eldesouki, Mohamed H. , Farraye, Francis A

Inflammatory Bowel Diseases | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ibd/izag134 | PMID 42485230 Get It

Abstract Background Immune dysregulation, immunosuppressive therapy and active inflammatory bowel disease (IBD) increase susceptibility to respiratory syncytial virus (RSV) infection. We evaluated the risk of RSV infection in patients with active and nonactive IBD. Methods Using the TriNetX Analytics Network from October 2024 through March 2025, we identified adult patients (aged ≥18 years) with IBD. Patients were classified as having active IBD if they had recent IBD complications, IBD-related surgery, or elevated inflammatory markers (within preceding 6 months); those without recent complications,surgeries, or elevated inflammatory markers were classified as having nonactive IBD within the same period. Outcomes were assessed within 180 days after the index date and included RSV infection, bacterial pneumonia, intensive care unit (ICU) admission, and mechanical ventilation. Results Among 141 763 patients (47 883 patients with active IBD, 93 880 patients with nonactive IBD), 2879 patients with active IBD and 3583 with nonactive IBD received the RSV vaccination. After matching, each cohort included 46 308 patients. Active IBD was associated with higher odds of RSV infection (adjusted odds ratio [aOR], 1.55; 95% CI, 1.18-2.04), bacterial pneumonia (aOR, 2.58; 95% CI, 2.08-3.19), ICU admissions (aOR, 2.07; 95% CI, 1.88-2.28), and mechanical ventilation (aOR, 2.41; 95% CI, 2.01-2.88). RSV risk remained higher among patients with active IBD both with and without systemic corticosteroid exposure. Among RSV-vaccinated patients, RSV infection rates were not significantly different between active and nonactive IBD (aOR, 1.26; 95% CI, 0.78-1.79). Conclusion Patients with active IBD had higher risk of RSV infection. Increased RSV risk was observed both among patients with active IBD with and without systemic corticosteroid exposure. Among RSV-vaccinated patients, RSV infection rates were not significantly different between active and nonactive IBD. Further prospective studies are needed to validate these findings.
Ulcerative Colitis Management in Adults
Loeb, Lauren , Davis, Andrew M., Kinnucan, Jami A., Loeb, Lauren P, Kinnucan, Jami

JAMA | July 22, 2026 | Volume: 336 | Issue: 12 | Pages: 1061

10.1001/jama.2026.8803 | PMID 42485028 Get It

This JAMA Clinical Guidelines Synopsis summarizes the American College of Gastroenterology’s (ACG) 2025 clinical guideline update on management of ulcerative colitis in adults.
Divergent Roles of Canonical and Non-Canonical Mismatch Repair in Regulating Temozolomide Sensitivity in Glioblastoma
Gupta, Shiv K. , Friedman, Teddy R., Sarkaria, Jann N. , Sarkaria, Jann N , Gupta, Shiv K , Jain, Sonia , Friedman, Teddy

International Journal of Molecular Sciences | July 22, 2026 | Volume: 27 | Issue: 14 | Pages: 6517

10.3390/ijms27146517 | PMID 42511857 Get It

Temozolomide (TMZ) remains the cornerstone of chemotherapeutic agent for glioblastoma (GBM), yet intrinsic and acquired resistance severely limits its clinical benefit. While O6-methylguanine-DNA methyltransferase (MGMT)–mediated repair of TMZ-induced O6-methylguanine (O6-meG) lesions has been extensively studied, the DNA mismatch repair (MMR) pathway is increasingly recognized as a key determinant of TMZ cytotoxicity. Canonical MMR, mediated by MutSα (MSH2–MSH6) and MutLα (MLH1–PMS2) complexes, recognizes O6-meG: thymine mispairs generated during replication and initiates futile repair cycles that culminate in replication stress, replication fork collapse, and apoptotic signaling; intact canonical MMR is, therefore, required for TMZ-induced cell death. Disruption of canonical MMR, frequently via acquired MSH6 mutations, confers TMZ tolerance and drives hypermutated recurrent GBM. Beyond mismatch correction, MMR proteins perform non-canonical functions in DNA damage signaling, replication stress responses, transcriptional regulation, chromatin dynamics, and immune modulation. These activities may shift the outcome from cytotoxic futile repair toward replication stress adaptation, Translesion synthesis (TLS)-mediated lesion tolerance, immune remodeling, and therapeutic resistance. Notably, partial attenuation or functional diversion of MMR may decouple lesion recognition from cytotoxic signaling, enabling TLS-mediated lesion tolerance without complete loss of MMR activity. This review integrates current insights into canonical and non-canonical MMR functions in GBM, defines their distinct contributions to TMZ sensitivity and resistance, and highlights therapeutic opportunities to exploit MMR-associated dependencies, including synthetic lethal strategies and immunotherapeutic vulnerabilities linked to MMR deficiency-driven hypermutation.
Acanthosis nigricans: Pathogenesis, differential diagnosis, and evidence-based management
Burroughs, Brian , Middleton, Hayden, Herndon, Justine , Burroughs, Brian T , Middleton, Hayden T.

Journal of Dermatology for Physician Assistants | July 22, 2026 | Volume: 20 | Issue: 3 | Pages: 3-7

10.1097/jdpa.0000000000000117 Get It

Acanthosis nigricans (AN) is a common dermatologic condition characterized by hyperpigmented, velvety plaques that most frequently affect intertriginous areas. Although often associated with insulin resistance and obesity, AN may also serve as a cutaneous marker of underlying endocrinologic disorders, medication effects, genetic syndromes, or internal malignancy. Recognition of AN provides an important opportunity for early identification of systemic disease and implementation of targeted management strategies. This review summarizes the pathogenesis and etiologic subtypes of AN, highlights key clinical features and differential diagnoses, and outlines an evidence-based diagnostic approach. Management strategies are discussed with emphasis on lifestyle modification, pharmacologic therapies, topical treatments, procedural interventions, and the strength of supporting evidence. Practical considerations relevant to physician assistants are emphasized throughout, including interdisciplinary care and patient education. Early recognition and appropriate management of AN can improve both dermatologic outcomes and overall patient health.
Use of dermoscopy and its association with skin lesion evaluation confidence among PAs in the United States
Middleton, Hayden T. , Young, Peter A. , Kolhoff, Sean, O’Laughlin, Danielle , Swanson, David C. , Sartori-Valinotti, Julio C., Weatherly, Renee M., Boswell, Christopher L. , Tapia, Amanda L. , Sartori‐Valinotti, Julio C.

Journal of Dermatology for Physician Assistants | July 22, 2026 | Volume: 20 | Issue: 3 | Pages: 14-20

10.1097/jdpa.0000000000000108 Get It

Introduction: Limited research explores dermoscopy use among physician associates (PAs), outside of one prior study examining dermoscopy in PA student education. This study sought to investigate dermoscopy use among practicing PAs and its impact on their overall diagnostic confidence, including in darker skin tones, when differentiating between benign and malignant skin lesions. Methods: An anonymous survey was developed in 2023 with input from experts in dermoscopy and survey creation to assess PA confidence in skin lesion evaluation as well as PA dermoscopy knowledge and use, perceptions, barriers to use, and prior education. The dermoscopy survey was included as an optional module in the 2024 American Academy of Physician Associates (AAPA) Salary Survey. Results: Of 3,174 invited PAs, 995 (31.4%) responded. Most had never used dermoscopy in practice (81%) but knew or recognized the term (71%). A majority (53%) believed PAs should be trained in dermoscopy during PA school, and 26% reported no interest in future dermoscopy use. Dermatology PAs reported more frequent dermoscopy use and generally greater confidence in evaluating skin lesions, both overall and in darker skin tones, than PAs in other specialties. PAs in surgical (OR=0.2, 95% CI 0.1-0.6) and medical (OR=0.3, 95% CI 0.2-0.5) subspecialties were less likely to use dermoscopy at least annually compared with PAs in primary care. PAs in rural areas were more likely to feel confident in differentiating skin lesions than those in urban areas (OR 2.9, 95% CI 1.7-5.0). Conclusion: Dermoscopy use is associated with higher overall skin lesion assessment confidence. Wider adoption, especially outside dermatology, requires training, increased advocacy, and expanded education.
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Sievers, Quinlan , Lu, Hao , Cool, Allison , Gajewski, Stefan , Kong, Tim , Noviski, Mark , Whelan, Sarah , Wang, Yuhan , Navarrete, Lizbeth Mendoza, Mi, Xiaoli , Mukerji, Ratul , Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Tan, Y. , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya‐Wen , Elechko, Jennifer, Phelps, Christopher B., Sekeres, Samantha, Bravo, Eduardo , Alencar, Alvaro J. , Islam, Prioty , Mato, Anthony R. , Noviski, Mark A , Wang, Yuhan , Mendoza Navarrete, Lizbeth , Ficici, Emel , Mukerji, Ratul , Iuliano, James N , Ye, Jordan , Sanchez Garcia De Los Rios, Mateo , Bousquet, Hugo , Tan, May , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya-Wen , Elechko, Jennifer , Maron, Maxim I , Phelps, Christopher B , Rahman, Jahan , Notti, Ryan Q , Sekeres, Samantha , Lamkin, Erica N , Bravo, Eduardo , Alencar, Alvaro J , Ewalt, Mark D , Islam, Prioty , Mato, Anthony , Roeker, Lindsey , Bhatt, Shruti , Taylor, Justin , Thompson, Meghan C , Hansen, Gwenn M , Abdel-Wahab, Omar , Lamkin, Erica , Ewalt, Mark D. , Roeker, Lindsey E. , Abdel‐Wahab, Omar

Cancer Discovery | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2159-8290.cd-26-0251 | PMID 42484277 Get It

Abstract Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. Here we sequenced serial CLL samples from patients enrolled in the phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTK A428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTK A428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTK A428D exhibited a competitive disadvantage. A crystal structure of BTK A428D revealed that the mutant aspartate clashes with the adenine ring of ATP and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTK A428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies.
Appendectomy before or after ulcerative colitis diagnosis is not associated with improved long-term outcomes: a multicenter real-world study
Desai, Aakash , Dapke, Kartik , Habib, Hany , Hashash, Jana, Farraye, Francis A, Desai, Aakash , Farraye, Francis A. , Habib, Hany

Inflammatory Bowel Diseases | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ibd/izag159 | PMID 42560773 Get It

Abstract Background Appendectomy has been proposed to influence ulcerative colitis (UC) outcomes, but its effect based on timing before or after diagnosis and long-term UC outcomes remains unclear. Materials and Methods Using TriNetX U.S. Collaborative Network, we identified adults with UC (2010-2024) who underwent appendectomy before or after diagnosis. Two 1:1 propensity score-matched comparisons were performed: appendectomy-before-UC and appendectomy-after-UC versus controls. The primary outcome was a 5-year composite of oral/intravenous (IV) corticosteroid use or colectomy. Secondary outcomes included individual composite outcomes and advanced therapy initiation in biologic-naive patients. Subgroup analyses stratified by age and biologic exposure were also performed. Results After matching, appendectomy after UC diagnosis showed no association with the composite outcome (aHR 0.98, 95% CI, 0.83-1.16), oral steroids (aHR 0.90, 95% CI, 0.75-1.09), IV steroids (aHR 1.11, 95% CI, 0.87-1.43), colectomy (aHR 1.24, 95% CI, 0.77-1.99), or advanced therapy initiation (aHR 0.97, 95% CI, 0.63-1.48). Appendectomy before UC diagnosis also showed no difference in the composite outcome (aHR 0.91, 95% CI, 0.76-1.09), oral steroids (aHR 0.88, 95% CI, 0.72-1.08), colectomy (aHR 0.99, 95% CI, 0.60-1.63), or advanced therapy initiation (aHR 0.77, 95% CI, 0.53-1.13). However, IV steroid use was reduced (aHR 0.68, 95% CI, 0.51-0.90, P = .006). In subgroup analyses, advanced therapy initiation was lower in patients aged 18-40 years following appendectomy after UC diagnosis (aHR 0.56, 95% CI, 0.33-0.96, P = .03). Conclusion Appendectomy was not associated with improved long-term UC outcomes of oral/IV steroid use, colectomy or initiation of advanced therapy regardless of timing.